Nonleptonic Two-Body Decays of D Mesons in Broken SU(3)

Decays of the D mesons to two pseudoscalars, to two vectors, and to pseudoscalar plus vector are discussed in the context of broken flavor SU(3). A few assumptions are used to reduce the number of parameters. Amplitudes are fit to the available data, and predictions of branching ratios for unmeasured modes are made.Comment: LaTeX, 24 page

SU(3)_flavor analysis of two-body weak decays of charmed baryons

We study two-body weak decays of charmed baryons \Lambda_c and \Xi_c into an octet or decuplet baryon and a pseudoscalar meson employing the SU(3) flavor symmetry. Using certain measured Cabibbo-favored modes, we fix the reduced amplitudes and predict the branching ratios of various decays of charmed baryons in the Cabibbo-enhanced, -suppressed and -doubly suppressed modes.Comment: 25 pages, No figure, Phys. Rev. D (to appear

SU(3) Breaking and D0-D0bar Mixing

The main challenge in the Standard Model calculation of the mass and width difference in the D0-D0bar system is to estimate the size of SU(3) breaking effects. We prove that D meson mixing occurs in the Standard Model only at second order in SU(3) violation. We consider the possibility that phase space effects may be the dominant source of SU(3) breaking. We find that y=(Delta Gamma)/(2Gamma) of the order of one percent is natural in the Standard Model, potentially reducing the sensitivity to new physics of measurements of D meson mixing.Comment: 18 pages; minor corrections, version to appear in Phys. Rev.

A randomised controlled trial for the effectiveness of intra-articular Ropivacaine and Bupivacaine on pain after knee arthroscopy: the DUPRA (DUtch Pain Relief after Arthroscopy)-trial

In this double-blinded, randomised clinical trial, the aim was to compare the analgesic effects of low doses of intra-articular Bupivacaine and Ropivacaine against placebo after knee arthroscopy performed under general anaesthesia. A total of 282 patients were randomised to 10 cc NaCl 0.9%, 10 cc Bupivacaine 0.5% or 10 cc Ropivacaine 0.75%. Patients received the assigned therapy by intra-articular injection after closure of the portal. Pain and satisfaction were measured at one, 4 h and 5-7 days after arthroscopy with Numerical Rating Scale (NRS) -scores. NSAID consumption was also recorded. One-h NRS-scores at rest were higher in the NaCl group compared with the Bupivacaine group (P <0.01), 1 h NRS-scores in flexion were higher in the NaCl group compared with the Bupivacaine (P <0.01) and Ropivacaine (P <0.01) groups. NRS-satisfaction at 4 h was higher for the Bupivacaine group compared with the NaCl group (P = 0.01). Differences in NRS-scores were significant but low in magnitude. NSAID consumption was lower in the Bupivacaine group compared with the NaCl group (P <0.01). The results of this randomised clinical trial demonstrate improved analgesia after administration of low doses of intra-articular Bupivacaine and Ropivacaine after arthroscopy of the knee. Considering reports of Bupivacaine and Ropivacaine being chondrotoxic agents and the relatively small improvement on patient comfort found in this trial, it is advised to use systemic anaesthetic instead of intra-articular Bupivacaine or Ropivacaine for pain relief after knee arthroscopy.

A Top Quark Soliton and its Anomalous Chromomagnetic Moment

We show that under the assumption of dynamical symmetry breaking of electro weak interactions by a top quark condensate, motivated by the Top Mode Standard Model, the top quark in this effective theory can be considered then as chiral color soliton (qualiton). This is realized in an effective four-fermion interaction with chiral $SU(3)_c$ as well as $SU(2)_L\otimes U_Y(1)$ symmetry. In the pure top sector the qualiton consists of a top valence quark and a Dirac sea of top and anti-top quark coupled to a color octet of Goldstone pions. The mass spectra, isoscalar quadratic radii and the anomalous chromomagnetic moment due to a non-trivial color form factor are calculated with zero and finite current top masses and effects at the Hadron Colliders are discussed. The anomalous chromomagnetic moment turns out to have a value consistent with the top production rates of the D0- and CDF-measurements.Comment: LaTeX, using RevTeX.sty and aps.sty, without figures, 16 pages, to be published in Physical Review D. Full postscript version and figures available on request or via ftp://hadron.tp2.ruhr-uni-bochum.de/preprint.tp2/1995/08-95.tar.g

In vivo imaging of pancreatic tumours and liver metastases using 7 Tesla MRI in a murine orthotopic pancreatic cancer model and a liver metastases model

<p>Abstract</p> <p>Background</p> <p>Pancreatic cancer is the fourth leading cause of tumour death in the western world. However, appropriate tumour models are scarce. Here we present a syngeneic murine pancreatic cancer model using 7 Tesla MRI and evaluate its clinical relevance and applicability.</p> <p>Methods</p> <p>6606PDA murine pancreatic cancer cells were orthotopically injected into the pancreatic head. Liver metastases were induced through splenic injection. Animals were analyzed by MRI three and five weeks following injection. Tumours were detected using T2-weighted high resolution sequences. Tumour volumes were determined by callipers and MRI. Liver metastases were analyzed using gadolinium-EOB-DTPA and T1-weighted 3D-Flash sequences. Tumour blood flow was measured using low molecular gadobutrol and high molecular gadolinium-DTPA.</p> <p>Results</p> <p>MRI handling and applicability was similar to human systems, resolution as low as 0.1 mm. After 5 weeks tumour volumes differed significantly (p < 0.01) when comparing calliper measurments (n = 5, mean 1065 mm³+/-243 mm³) with MRI (mean 918 mm³+/-193 mm³) with MRI being more precise. Histology (n = 5) confirmed MRI tumour measurements (mean size MRI 38.5 mm²+/-22.8 mm²versus 32.6 mm²+/-22.6 mm²(histology), p < 0,0004) with differences due to fixation and processing of specimens. After splenic injection all mice developed liver metastases with a mean of 8 metastases and a mean volume of 173.8 mm³+/-56.7 mm³after 5 weeks. Lymphnodes were also easily identified. Tumour accumulation of gadobutrol was significantly (p < 0.05) higher than gadolinium-DTPA. All imaging experiments could be done repeatedly to comply with the 3R-principle thus reducing the number of experimental animals.</p> <p>Conclusions</p> <p>This model permits monitoring of tumour growth and metastasis formation in longitudinal non-invasive high-resolution MR studies including using contrast agents comparable to human pancreatic cancer. This multidisciplinary environment enables radiologists, surgeons and physicians to further improve translational research and therapies of pancreatic cancer.</p

Clinical outcomes after anterior cruciate ligament injury: panther symposium ACL injury clinical outcomes consensus group

© 2020, The Author(s). Purpose: A stringent outcome assessment is a key aspect for establishing evidence-based clinical guidelines for anterior cruciate ligament (ACL) injury treatment. The aim of this consensus statement was to establish what data should be reported when conducting an ACL outcome study, what specific outcome measurements should be used and at what follow-up time those outcomes should be assessed. Methods: To establish a standardized approach to assessment of clinical outcome after ACL treatment, a consensus meeting including a multidisciplinary group of ACL experts was held at the ACL Consensus Meeting Panther Symposium, Pittsburgh, PA; USA, in June 2019. The group reached consensus on nine statements by using a modified Delphi method. Results: In general, outcomes after ACL treatment can be divided into four robust categories—early adverse events, patient-reported outcomes, ACL graft failure/recurrent ligament disruption and clinical measures of knee function and structure. A comprehensive assessment following ACL treatment should aim to provide a complete overview of the treatment result, optimally including the various aspects of outcome categories. For most research questions, a minimum follow-up of 2 years with an optimal follow-up rate of 80% is necessary to achieve a comprehensive assessment. This should include clinical examination, any sustained re-injuries, validated knee-specific PROs and Health-Related Quality of Life questionnaires. In the mid- to long-term follow-up, the presence of osteoarthritis should be evaluated. Conclusion: This consensus paper provides practical guidelines for how the aforementioned entities of outcomes should be reported and suggests the preferred tools for a reliable and valid assessment of outcome after ACL treatment. Level of evidence: V